FMS is the receptor for macrophage colony stimulating factor (M-CSF or CSF-1) and is essential for the differentiation and survival of most macrophages, microglia and osteoclasts Infiltration of macrophages and high levels of M-CSF in serum are associated with poor prognosis in human breast, ovarian and endometrial cancers. Consequently, inhibitors of FMS have considerable therapeutic potential for the treatment of cancer, as well as macrophage-mediated inflammatory disease and bone disorders caused by excessive osteoclastogenesis . Here I report the identification of four clinically advanced small molecule kinase inhibitors which can also target FMS, as shown by various biochemical and cell-based assays. The inhibitors I identified are ima...
Background: Multiple Myeloma (MM) is currently incurable, with a median survival of 5-7 years post d...
International audienceOsteosarcoma is the most frequent primary bone tumor that develops mainly duri...
International audienceOsteosarcoma is the most frequent primary bone tumor that develops mainly duri...
FMS is the receptor for macrophage colony stimulating factor (M-CSF or CSF-1) and is essential for ...
Copyright © 2005 by American Society of HematologyFrom the Division of Haematology, Hanson Institute...
Imatinib is a selective protein tyrosine kinase inhibitor currently used in the treatment of chronic...
Copyright © 2006 by American Society of HematologyFrom the Myeloma and Mesenchymal Research Laborato...
Summary The effect of the multi-kinase inhibitor Sorafenib was investigated in an in vitro model of ...
Osteoclasts (OCs) are large multinucle-ated cells derived from progenitor cells of the monocyte-macr...
Understanding the factors that regulate the growth and differentiation of haemopoietic stem cells (H...
BACKGROUND Multiple myeloma (MM) is an hematological malignancy characterized by the accumulation of...
There is currently a demand for new highly efficient and specific drugs to treat osteoporosis, a chr...
There is currently a demand for new highly efficient and specific drugs to treat osteoporosis, a chr...
Background: Multiple Myeloma (MM) is currently incurable, with a median survival of 5-7 years post d...
Objectives: To investigate the role of non-receptor tyrosine kinases (NRTKs) in inflammation-induced...
Background: Multiple Myeloma (MM) is currently incurable, with a median survival of 5-7 years post d...
International audienceOsteosarcoma is the most frequent primary bone tumor that develops mainly duri...
International audienceOsteosarcoma is the most frequent primary bone tumor that develops mainly duri...
FMS is the receptor for macrophage colony stimulating factor (M-CSF or CSF-1) and is essential for ...
Copyright © 2005 by American Society of HematologyFrom the Division of Haematology, Hanson Institute...
Imatinib is a selective protein tyrosine kinase inhibitor currently used in the treatment of chronic...
Copyright © 2006 by American Society of HematologyFrom the Myeloma and Mesenchymal Research Laborato...
Summary The effect of the multi-kinase inhibitor Sorafenib was investigated in an in vitro model of ...
Osteoclasts (OCs) are large multinucle-ated cells derived from progenitor cells of the monocyte-macr...
Understanding the factors that regulate the growth and differentiation of haemopoietic stem cells (H...
BACKGROUND Multiple myeloma (MM) is an hematological malignancy characterized by the accumulation of...
There is currently a demand for new highly efficient and specific drugs to treat osteoporosis, a chr...
There is currently a demand for new highly efficient and specific drugs to treat osteoporosis, a chr...
Background: Multiple Myeloma (MM) is currently incurable, with a median survival of 5-7 years post d...
Objectives: To investigate the role of non-receptor tyrosine kinases (NRTKs) in inflammation-induced...
Background: Multiple Myeloma (MM) is currently incurable, with a median survival of 5-7 years post d...
International audienceOsteosarcoma is the most frequent primary bone tumor that develops mainly duri...
International audienceOsteosarcoma is the most frequent primary bone tumor that develops mainly duri...